Literature DB >> 31409487

Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.

Toni P Kilts1, Gretchen E Glaser1, Carrie L Langstraat1, Amanika Kumar1, Amy L Weaver2, Michaela E Mc Gree2, Bobbie S Gostout1, Karl C Podratz1, Sean C Dowdy1, William A Cliby1, Andrea Mariani1, Jamie N Bakkum-Gamez3.   

Abstract

OBJECTIVE: To compare two published risk stratification models (Milwaukee Model vs. Mayo Criteria) to predict lymphatic dissemination (LD) in endometrioid endometrial cancer (EC).
METHODS: Patients with stage I-III EC undergoing surgery from 1/1/2004-9/30/2013 were retrospectively reviewed and classified as low-risk vs at-risk for LD using two independent risk models. LD was defined as positive nodes at surgery or lymph node recurrence within 2 years of surgery after negative lymph node dissection (LND) or when LND was not performed. False positive (FP) and false negative (FN) rates for each risk model were calculated.
RESULTS: Among 1103 patients, 81 (7.3%) had LD (72 positive LN and 9 LN recurrences), and most (90.2%) had stage I EC. The Milwaukee Model yielded a low at-risk rate for LD (38.1%) but a high FN rate (13.6%, 95% CI 7.0-23.0). The traditional Mayo Criteria using a cut-off of 2 cm for tumor diameter (TD) had a higher at-risk rate for LD (69.5%) but a FN rate of 0% (95% CI, 0-4.5). Modifying the Mayo Criteria using a TD cutoff of ≤3 cm identified fewer women at-risk (56.8% vs. 69.5%) and had a lower FP rate (53.6% vs. 67.1%), but had a higher FN rate (3.7%, 95% CI, 0.8-10.4).
CONCLUSIONS: The Milwaukee Model had the lowest at-risk rate of LD but an unacceptable FN rate. Modifying the Mayo Criteria by increasing the TD cutoff from the traditional ≤2 cm to ≤3 cm would spare an estimated 13.5% of patients LND, but the accompanying FN rate is unacceptably high. The traditional Mayo Criteria for low-risk EC remains the most sensitive in determining which patients LND can be omitted.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Tumor diameter; Tumor grade

Mesh:

Year:  2019        PMID: 31409487     DOI: 10.1016/j.ygyno.2019.08.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients.

Authors:  Xiaoying Jin; Chunjuan Shen; Xiaodi Yang; Yayuan Yu; Jianzhang Wang; Xuan Che
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

2.  Development and validation of predictive model for lymph node metastasis in endometrial cancer: a SEER analysis.

Authors:  Xingchen Li; Yuan Cheng; Yangyang Dong; Jingyi Zhou; Zhiqi Wang; Xiaoping Li; Jianliu Wang
Journal:  Ann Transl Med       Date:  2021-04

3.  Is preoperative ultrasound tumor size a prognostic factor in endometrial carcinoma patients?

Authors:  Marco Ambrosio; Antonio Raffone; Andrea Alletto; Chiara Cini; Francesco Filipponi; Daniele Neola; Matilde Fabbri; Alessandro Arena; Diego Raimondo; Paolo Salucci; Manuela Guerrini; Antonio Travaglino; Roberto Paradisi; Antonio Mollo; Renato Seracchioli; Paolo Casadio
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 4.  Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review.

Authors:  Lirong Zhai; Xiwen Zhang; Manhua Cui; Jianliu Wang
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.